Radiopharm Theranostics Ltd (RADX) Payables (2023 - 2026)

Radiopharm Theranostics (RADX) has reported Payables for 4 consecutive years, with $208867.2 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 14.22% year-over-year to $208867.2 in Q2 2026; TTM through Jun 2026 was $208867.2, a 14.22% decrease from a year earlier, with the FY2026 full-year figure at $199976.8, down 99.47% from the prior year.
• Payables was $208867.2 for Q2 2026 at Radiopharm Theranostics, down from $243479.8 in the prior quarter.
• Over five years, Payables peaked at $34.6 million in Q4 2024 and troughed at $208867.2 in Q2 2026.
• A 4-year average of $8.1 million and a median of $250192.6 in 2024 frame the typical range for Payables.
• Across the five-year window, Payables sank 95.12% in 2024 and fell 2.68% in 2025, its largest moves.
• Over 4 years, Payables stood at $5.1 million in 2023, then soared by 576.18% to $34.6 million in 2024, then sank by 99.3% to $243479.8 in 2025, then retreated by 14.22% to $208867.2 in 2026.
• The last three Payables figures came in at $208867.2 (Q2 2026), $243479.8 (Q2 2025), and $34.6 million (Q4 2024), per Business Quant data.